Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.54 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL693350 | 1.00 | TSHR (0.65) | TSHRHTR2CHTR2BBACE1CTSC | |
| Hydrochloric Acid SCHEMBL1000787 | 1.00 | TSHR (0.65) | TSHRHTR2CHTR2BBACE1CTSC | |
| SCHEMBL4069956 | 0.98 | TSHR (0.63) | TSHRHTR2CHTR2BBACE1CTSC | |
| SCHEMBL693351 | 0.98 | TSHR (0.63) | TSHRHTR2CHTR2BBACE1CTSC | |
| SCHEMBL630517 | 0.98 | TSHR (0.63) | TSHRHTR2CHTR2BBACE1CTSC | |
| Hydrochloric Acid SCHEMBL630941 | 0.96 | TSHR (0.64) | TSHRHTR2CHTR2BBACE1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL630943 | 0.96 | TSHR (0.64) | TSHRHTR2CHTR2BBACE1ALDH1A1 | |
| SCHEMBL6727374 | 0.94 | TSHR (0.61) | TSHRHTR2CHTR2BBACE1GLA | |
| SCHEMBL630942 | 0.94 | TSHR (0.61) | TSHRHTR2CHTR2BBACE1GLA | |
| SCHEMBL28676037 | 0.93 | TSHR (0.60) | TSHRHTR2CHTR2BBACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011092-A | Method for preparing Pal-GQPR by LPPS | 富乐马鸿凯（大连）医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-107474107-B | Process for the preparation of GLYX-13 and compounds useful for the preparation of GLYX-13 | 江苏恩华药业股份有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-107474107-A | GLYX 13 preparation method and the compound for preparing GLYX 13 | 江苏恩华药业股份有限公司 | 2017-12-15 | — | — | CN | claimed |
| CN-102241604-B | Amino acid modified curcumin, synthesis method thereof, and application thereof | UNIV CAPITAL MEDICAL | 2013-11-06 | — | — | CN | claimed |
| US-5177006-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-01-05 | — | — | US | claimed |
| JP-8253497-A | — | — | None | — | — | JP | disclosed |
| JP-60142999-A | — | — | None | — | — | JP | disclosed |
| JP-10109999-A | — | — | None | — | — | JP | disclosed |
| CN-122011092-A | Method for preparing Pal-GQPR by LPPS | 富乐马鸿凯（大连）医药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122011092-A | Method for preparing Pal-GQPR by LPPS | 富乐马鸿凯（大连）医药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| EP-4448545-B1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2025-08-20 | — | — | EP | disclosed |
| EP-0080283-A1 | N-carboxyalkylproline-containing tripeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4386075-A | IMPROVING KIDNEY FUNCTION | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0000833-B1 | DERIVATIVES OF PHOSPHONOACYL PROLINES AND THEIR PHARMACEUTICAL USE | E.R. Squibb & Sons, Inc. (US) | 1981-09-02 | — | — | EP | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
| US-4151172-A | Phosphonoacyl prolines and related compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| EP-0000833-A1 | Derivatives of phosphonoacyl prolines and their pharmaceutical use | E.R. Squibb & Sons, Inc. (US) | 1979-02-21 | — | — | EP | disclosed |